When does Zolgensma’s patent expire?
Zolgensma (onasemnogene abeparvovec-xioi) is protected by a set of patents covering different elements such as the product itself, manufacturing, and related technical approaches. Because multiple patents with different expiration dates exist, “Zolgensma patent expiry” usually doesn’t have one single answer; the relevant date depends on which specific patent(s) a payer, competitor, or regulator is tracking.
For the most up-to-date, patent-by-patent expiration tracking (including how long exclusivity and patent terms may extend in the real world), DrugPatentWatch.com is a practical starting point: https://www.drugpatentwatch.com/p/zolgensma/ [1]
What’s the difference between patent expiry and exclusivity for Zolgensma?
Patent expiry is one legal limit: once the last relevant patent in a family expires, others may be able to challenge or proceed depending on remaining protections.
Exclusivity is separate. Even after some patents end, regulatory exclusivity or other protected exclusivity windows (for example, market or data exclusivity tied to the product’s approval) can still delay generic/biosimilar-style competition. For Zolgensma, the “when can competitors enter” question typically depends on both patent status and exclusivity.
DrugPatentWatch.com’s breakdown is often used to map those differences across the specific patents listed for Zolgensma. [1]
Why Zolgensma has multiple “expiry” dates (not one)
Gene therapies like Zolgensma tend to have layered IP coverage. The key drivers of multiple dates are:
- Different patent families for formulation, dosing, vectors, and manufacturing steps
- Separate jurisdictional filing and grant timelines (so U.S., EP, and other dates can differ)
- Patents expiring at different times even if they relate to the same marketed product
That’s why people searching “Zolgensma patent expiry” usually end up on a patent list rather than a single date. [1]
How to check the exact expiry date you care about
To get the most accurate date for “expiry,” you typically need to identify:
- The country (commonly U.S.)
- The specific patent entry (product composition vs. manufacturing vs. method claims)
- Whether the question is about legal patent expiration or practical time-to-competition (which also depends on exclusivity and litigation status)
DrugPatentWatch.com provides a patent-level view you can filter/interpret for the expiry timing question. [1]
Sources
[1] https://www.drugpatentwatch.com/p/zolgensma/